DOI QR코드

DOI QR Code

참식나무(Neolitsea sericea) 기주 참나무겨우살이(Taxillus yadoriki) 가지 추출물의 폐암세포 A549에 대한 세포생육 억제활성

Inhibitory Effect of the Branch Extracts from Taxillus yadoriki Parasitic to Neolitsea sericea against the Cell Proliferation in Human Lung Cancer Cells, A549

  • 박수빈 (국립안동대학교 생약자원학과, 대학원) ;
  • 김하나 (국립안동대학교 생약자원학과, 대학원) ;
  • 김정동 (국립안동대학교 생약자원학과) ;
  • 박광훈 (국립산림과학원 산림약용자원연구소) ;
  • 어현지 (국립산림과학원 산림약용자원연구소) ;
  • 안미연 (국립안동대학교 생약자원학과, 대학원) ;
  • 정진부 (국립안동대학교 생약자원학과)
  • Park, Su Bin (Department of Medicinal Plant Resources, Andong National University) ;
  • Kim, Ha Na (Department of Medicinal Plant Resources, Andong National University) ;
  • Kim, Jeong Dong (Department of Medicinal Plant Resources, Andong National University) ;
  • Park, Gwang Hun (Forest Medicinal Resources Research Center, National Institute of Forest Science) ;
  • Eo, Hyun Ji (Forest Medicinal Resources Research Center, National Institute of Forest Science) ;
  • An, Mi-Yun (Department of Medicinal Plant Resources, Andong National University) ;
  • Jeong, Jin Boo (Department of Medicinal Plant Resources, Andong National University)
  • 투고 : 2019.01.21
  • 심사 : 2019.03.04
  • 발행 : 2019.04.30

초록

이상의 연구 결과로 미루어 볼 때, 참식나무 기주 참나무겨우살이(TY-NS-B)는 $GSK3{\beta}$에 의한 ${\beta}$-catenin 인산화에 의존하지 않는 ${\beta}$-catenin의 분해 유도를 통해 암세포의 생육과 관련된 c-Myc의 발현을 억제하며, 이것은 비소세포성 폐암의 생육억제와 관련이 있는 것으로 판단된다. 또한, 본 결과는 항암을 위한 대체보완소재로 참식나무 기주 참나무겨우살이의 활용이 가능할 것으로 판단된다. 그러나 추가적 연구를 통해 참식나무 기주 참나무겨우살이가 어떻게 ${\beta}$-catenin의 분해 유도에 관여하는지에 대한 기전연구와 관련 활성물질의 분석연구가 필요할 것으로 사료된다.

In this study, we evaluated the anti-cancer activity and potential molecular mechanism of 70% ethanol extracts of branches from Taxillus yadoriki parasitic to Neolitsea sericea (TN-NS-B) against human lung cancer cells, A549. TY-NS-B dose-dependently suppressed the growth of A549 cells. TY-NS-B decreased ${\beta}$-catenin protein level, but not mRNA level in A549 cells. The downregulation of ${\beta}$-catenin protein level by TY-NS-B was attenuated in the presence of MG132. Although TY-NS-B phosphorylated ${\beta}$-catenin protein, the inhibition of $GSK3{\beta}$ by LiCl did not blocked the reduction of ${\beta}$-catenin by TY-NS-B. In addition, TY-NS-B decreased ${\beta}$-catenin protein in A549 cells transfected with Flag-tagged wild type ${\beta}$-catenin or Flag-tagged S33/S37/T41 mutant ${\beta}$-catenin construct. Our results suggested that TN-NS-B may downregulate ${\beta}$-catenin protein level independent on $GSK3{\beta}$-induced ${\beta}$-catenin phosphorylation. Based on these findings, TY-NS-B may be a potential candidate for the development of chemopreventive or therapeutic agents for human lung cancer.

키워드

JOSMBA_2019_v32n2_109_f0001.png 이미지

Fig. 1. Effect of TY-NS-B on the cell growth and β-catenin expression in human lung cancer cells, A549. (A) Cell growth was evaluated by MTT assay at 24 h after TY-NS-B treatment. *p < 0.05 compared to cell without TY-NS-B. (B) A549 cells were treated with TY-NS-B at the indicated concentrations for 24 h. Western blot analysis was performed against β-catenin. Actin was used as internal control. (C) A549 cells were treated with TY-NS-B (25 ㎍/mL) for the indicated times. Western blot analysis was performed against β-catenin. Actin was used as internal control. (D) RT-PCR analysis of β-catenin and c-Myc gene expression was performed at 24 h after TY-NS-B treatment.

JOSMBA_2019_v32n2_109_f0002.png 이미지

Fig. 2. Effect of TY-NS-B on β-catenin proteasomal degradation in human lung cancer cells, A549. (A) A549 cells were pretreat with 20 μM of MG132 for 2 h and then co-treated with TY-NS-B for 10 h. (B) A549 cells were treated with TY-NS-B for the indicated times (C) A549 cells were pretreat with 20 mM of LiCl for 2 h and then co-treated with TY-NS-B for 10 h. (D) A549 cells were transfected with Flag-tagged wild type β-catenin or Flag-tagged S33/S37/T41 mutant β-catenin construct for 48 h and the co-treated with TY-NS-B for 12 h. Western blot analysis was performed against β-catenin. Actin was used as internal control.

Table 1. Sequence of oligonucleotide primers used for RT-PCR

JOSMBA_2019_v32n2_109_t0001.png 이미지

참고문헌

  1. Eisenberg, D.M., R.B. Davis, S.L. Ettner, S. Appel, S. Wilkey, M. Van Rompay and R.C. Kessler. 1998. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-1575. https://doi.org/10.1001/jama.280.18.1569
  2. Erridge, S.C., H. Moller, A. Price and D. Brewster. 2007. International comparisons of survival from lung cancer: pitfalls and warnings. Nat. Rev. Clin. Oncol. 4:578-590. https://doi.org/10.1038/ncponc0930
  3. Guessous, I., J. Cornuz and F. Paccaud. 2007. Lung cancer screening: current situation and perspective. Swiss Med. Wkly. 137:304-311.
  4. Hwang, S.Y., X. Deng, S Byun, C Lee, S.J. Lee, H. Suh, J. Zhang, Q. Kang, T. Zhang, K.D. Westover, A. Mandinova and S.W. Lee. 2016. Direct targeting of ${\beta}$-catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/${\beta}$-catenin signaling. Cell Rep. 16:28-36. https://doi.org/10.1016/j.celrep.2016.05.071
  5. Jin, J., P. Zhan, M. Katoh, S.S. Kobayashi, K. Phan, H. Qian, H. Li, X. Wang, X. Wang and Y. Song. 2017. Prognostic significance of ${\beta}$-catenin expression in patients with nonsmall cell lung cancer: a meta-analysis. Transl. Lung Cancer Res. 6:97-108. https://doi.org/10.21037/tlcr.2017.02.07
  6. Jung K.W., Y.J. Won, H.J. Kong and E.S. Lee. 2018. Prediction of cancer incidence and mortality in Korea, 2018. Cancer Res. Treat. 50:317-323. https://doi.org/10.4143/crt.2018.142
  7. Kim, C.S., S.Y. Kim, B.Y. Sun and J.S. Yi. 2013. A review of the taxonomic and ecological characteristics of Korean mistletoe type (Viscum, Korthalsella, Loranthus and Taxillus). Korean J. Pl. Taxon. 43:81-89. https://doi.org/10.11110/kjpt.2013.43.2.81
  8. Kim, S.M., J.H. Park, H.O. Boo, S.G. Song and H.Y. Park. 2017. In vitro comparision of biological activities of solvent fraction extracts from Orostachys japonicus. Korean J. Plant Res. 30(2):133-143. https://doi.org/10.7732/kjpr.2017.30.2.133
  9. Li, L.F., Z.J. Wei, H. Hong and B. Jiang. 2014. Abnormal ${\beta}$-catenin immunohistochemical expression as a prognostic factor in gastric cancer: A meta-analysis. Wold J. Gastroenterol. 20:12312-12321.
  10. Lin, L., K. Cheng, Z. Xie, C. Chen, L. Chen, Y. Huang and Z. Liang. 2019. Purification and characterization a polysaccharide from Hedyotis diffusa and its apoptosis inducing activity toward human lung cancer cell line A549. Int. J. Biol. Macromol. 122:64-71. https://doi.org/10.1016/j.ijbiomac.2018.10.077
  11. Liu, C., Y. Li, M. Semenov, C. Han, G.H. Baeg, Y. Tan, Z. Zhang, X. Lin and X. He. 2002. Control of ${\beta}$-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837-847. https://doi.org/10.1016/S0092-8674(02)00685-2
  12. Mengoni, F., M. Lichtner, L. Battinelli, M. Marzi, C.M. Mastroianni, V. Vullo and G. Mazzanti. 2002. In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells. Planta Med. 68:111-114. https://doi.org/10.1055/s-2002-20256
  13. Ovesna, Z., A. Vachalkova, H. Horvathova and D. Tothova. 2004. Pentacyclic triterpenoid acids: new chemoprotective compounds. Neoplasma 51:327-333.
  14. Pacheco-Pinedo, E.C., A.C. Durham, K.M. Stewart, A.M. Goss, M.M. Lu, F.J. Demayo and E.E. Morrisey. 2011. Wnt/${\beta}$-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J. Clin. Invest. 121:1935-1945. https://doi.org/10.1172/JCI44871
  15. Park, S.B., G.H. Park, H.N. Kim, H.J. Son, H.M. Song, H.S. Kim, H.J. Jeong and J.B. Jeong. 2018a. Anti-inflammatory effect of the extracts from the branch of Taxillus yadoriki being parasitic in Neolitsea Sericea in LPS-stimulated RAW264.7 cells. Biomed. Pharmacother. 104:1-7. https://doi.org/10.1016/j.biopha.2018.05.034
  16. Park, S.B., G.H. Park, H.N. Kim, H.M. Song, H.J. Song, J.A. Park, H.S. Kim and J.B. Jeong. 2018b. Ethanol extracts from the branch of Taxillus yadoriki parasitic to Neolitsea sericea induces cyclin D1 proteasomal degradation through cyclin D1 nuclear export. BMC Complement. Altern. Med. 18:189. https://doi.org/10.1186/s12906-018-2258-x
  17. Risberg, T., E. Lund, E. Wist, S. Kaasa and T. Wilsgaard. 1998. Cancer patients use of nonproven therapy: a 5-year follow-up study. J. Clin. Oncol. 16:6-12. https://doi.org/10.1200/JCO.1998.16.1.6
  18. Sadava, D., J. Ahn, M. Zhan, M.L. Pang, J. Ding and S.E. Kane. 2002. Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Chemother. Pharmacol. 49:261-266. https://doi.org/10.1007/s00280-002-0427-5
  19. Safayhi, H. and E.R. Sailer. 1997. Anti-inflammatory actions of pentacyclic triterpenes. Planta Med. 63:487-493. https://doi.org/10.1055/s-2006-957748
  20. Scanlon, C.S., E.A. Van Tubergen, R.C. Inglehart and N.J. D'Silva. 2013. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J. Dent. Res. 92:114-121. https://doi.org/10.1177/0022034512467352
  21. Schmalhofer, O., S. Brabletz and T.E. Brabletz. 2009. Cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28:151-166. https://doi.org/10.1007/s10555-008-9179-y
  22. Siegel, R.L., K.D. Miller and A. Jemal. 2018. Cancer statistics, 2018. CA Cancer J. Clin. 38:7-30. https://doi.org/10.3322/caac.21442
  23. Tam, W.L. and R.A. Weinberg. 2013 The epigenetics of epithelialmesenchymal plasticity in cancer. Nat Med. 19:1438-1449. https://doi.org/10.1038/nm.3336
  24. Weissenstein, U., U.D. Toffol-Schmidt, S. Baumgartner and K. Urech. 2011. Effect of Viscum album lipophilic extract on human immunocompetent cells in vitro. Phytomedicine 18:22-23.
  25. Xu, C., N.G. Kim and B.M. Gumbiner. 2010. Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 8:4032-4039. https://doi.org/10.4161/cc.8.24.10111
  26. Yin, X., J. Zhou, C. Jie, D. Xing and Y. Zhang. 2004. Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci. 75:2233-2244. https://doi.org/10.1016/j.lfs.2004.05.015